drugset / Trial / NCT00225264

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264

Phase 3 Completed 458 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to compare the effects of pioglitazone, once daily (QD), versus glimepiride on the amount of thickening of the carotid artery.

Timeline

Start
2003-10
Primary completion
2006-05
Completion
2006-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 4 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral